MedPath

Gate Neurosciences, Inc.

Gate Neurosciences, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2018-01-01
Employees
11
Market Cap
-
Website
http://www.gateneuro.com

GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

Phase 2
Recruiting
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2024-08-09
Last Posted Date
2025-06-22
Lead Sponsor
Gate Neurosciences, Inc
Target Recruit Count
164
Registration Number
NCT06547489
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

University of Alabama at Birmingham-Huntsville, Huntsville, Alabama, United States

🇺🇸

Wr-Pri, Llc, Encino, California, United States

and more 26 locations

Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers

Phase 1
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
First Posted Date
2022-10-28
Last Posted Date
2023-04-11
Lead Sponsor
Gate Neurosciences, Inc
Target Recruit Count
40
Registration Number
NCT05597241
Locations
🇺🇸

Woodland Research Northwest, Rogers, Arkansas, United States

Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers

Phase 1
Terminated
Conditions
Major Depressive Disorder
Excessive Sleepiness
Interventions
First Posted Date
2020-11-05
Last Posted Date
2022-08-03
Lead Sponsor
Gate Neurosciences, Inc
Target Recruit Count
18
Registration Number
NCT04618263
Locations
🇺🇸

Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States

AGN-241751 in the Treatment of Major Depressive Disorder

Phase 1
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
First Posted Date
2018-10-31
Last Posted Date
2023-07-07
Lead Sponsor
Gate Neurosciences, Inc
Target Recruit Count
226
Registration Number
NCT03726658
Locations
🇺🇸

Alea Research, Phoenix, Arizona, United States

🇺🇸

Collaborative Neuroscience Network, LLC, Garden Grove, California, United States

🇺🇸

Atlanta Center for Medical Research, Atlanta, Georgia, United States

and more 2 locations

AGN-241751 in the Treatment of Major Depressive Disorder

Phase 2
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: Placebo
First Posted Date
2018-07-13
Last Posted Date
2022-08-03
Lead Sponsor
Gate Neurosciences, Inc
Target Recruit Count
251
Registration Number
NCT03586427
Locations
🇺🇸

Health Initiatives Research PLLC, Fayetteville, Arkansas, United States

🇺🇸

Synexus US - Cerritos, Cerritos, California, United States

🇺🇸

Wake Research - Pharmacology Research Institute, Newport Beach, California, United States

and more 21 locations
© Copyright 2025. All Rights Reserved by MedPath